ArticleCell reports. Medicine2026
Single-cell spatial analysis stratifies lung adenocarcinoma with rare actionable mutations and reveals immune-modulatory cellular crosstalk.
Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LUAD) harboring distinct actionable oncogenic mutations exhibits differential responses to immune checkpoint inhibitors (ICI); however, the underlying mechanisms remain elusive. Here, we report comprehensive single-cell spatial atlases of tumors from 38 LUAD patients, predominantly harboring rare actionable oncogenes. Stratifying patients by consensus meta-programs (MP) reveals ICI-MP-H (high) and ICI-MP-L (low) subgroups. The ICI-MP-H group exhibits significant enrichment of the E3-IFI6 epithelial subpopulation, which displays high expression of interferon- and antigen presentation-related genes. Spatially, E3-IFI6 is adjacent to the Ma-MHC myeloid subpopulation; both co-enrich in a specific niche and likely interact via the APP-CD74 axis. Functional assays confirm that IFI6 overexpression in LUAD cell lines promotes proinflammatory macrophage activation. Our study systematically characterizes the features of the tumor ecosystem for different driver oncogene mutations, providing a theoretical basis for future clinical implementation of ICI therapy in patients with LUAD carrying rare mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.